 | • レポートコード：MRC2102QY15776 • 出版社/出版日： / 2021年1月 • レポート形態：英文、PDF、149ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥592,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥888,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,184,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYリサーチ社の本調査レポートでは、世界の泌尿器がん治療薬市場について種類別（ゾーフィゴ（ラジウムRa223ジクロリド）、ジェブタナ（カバジタキセル）、インライタ（アキシチニブ）、ヴォトリエント（パゾパニブ塩酸塩）、スーテント（スニチニブリンゴ酸塩）、ザイティガ（酢酸アビラテロン）、エクスタンディ（エンザルタミド）、オプジーボ（ニボルマブ）、プロベンジ（シプリューセル- T））、用途別（病院、医学研究所、その他）、地域別（米国、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・泌尿器がん治療薬市場の概要 ・世界の主要地域別泌尿器がん治療薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の泌尿器がん治療薬市場規模2015-2026：種類別（ゾーフィゴ（ラジウムRa223ジクロリド）、ジェブタナ（カバジタキセル）、インライタ（アキシチニブ）、ヴォトリエント（パゾパニブ塩酸塩）、スーテント（スニチニブリンゴ酸塩）、ザイティガ（酢酸アビラテロン）、エクスタンディ（エンザルタミド）、オプジーボ（ニボルマブ）、プロベンジ（シプリューセル- T）） ・世界の泌尿器がん治療薬市場規模2015-2026：用途別（病院、医学研究所、その他） ・泌尿器がん治療薬の米国市場規模2015-2020 ・泌尿器がん治療薬のヨーロッパ市場規模2015-2020 ・泌尿器がん治療薬の中国市場規模2015-2020 ・泌尿器がん治療薬の日本市場規模2015-2020 ・泌尿器がん治療薬の東南アジア市場規模2015-2020 ・泌尿器がん治療薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・泌尿器がん治療薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・泌尿器がん治療薬の市場動向・機会・課題 ・調査の結論 |
Global Urological Cancer Therapeutics Drugs Market is estimated to reach $48.6 billion by 2025 Says, .Now a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs.
Market Analysis and Insights: Global Urological Cancer Therapeutics Drugs Market
The global Urological Cancer Therapeutics Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global Urological Cancer Therapeutics Drugs Scope and Market Size
The global Urological Cancer Therapeutics Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Urological Cancer Therapeutics Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Urological Cancer Therapeutics Drugs market is segmented into
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Segment by Application, the Urological Cancer Therapeutics Drugs market is segmented into
Hospital
Medical Research Laboratory
Others
The Urological Cancer Therapeutics Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Urological Cancer Therapeutics Drugs market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Urological Cancer Therapeutics Drugs Market Share Analysis
Urological Cancer Therapeutics Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Urological Cancer Therapeutics Drugs business, the date to enter into the Urological Cancer Therapeutics Drugs market, Urological Cancer Therapeutics Drugs product introduction, recent developments, etc.
The major vendors covered:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
1 Urological Cancer Therapeutics Drugs Market Overview
1.1 Urological Cancer Therapeutics Drugs Product Scope
1.2 Urological Cancer Therapeutics Drugs Segment by Type
1.2.1 Global Urological Cancer Therapeutics Drugs Sales by Type (2020-2026)
1.2.2 Xofigo (radium Ra 223 dichloride)
1.2.3 Jevtana (cabazitaxel)
1.2.4 Inlyta (axitinib)
1.2.5 Votrient (pazopanib hydrochloride)
1.2.6 Sutent (sunitinib malate)
1.2.7 Zytiga (abiraterone acetate)
1.2.8 Xtandi (enzalutamide)
1.2.9 Opdivo (nivolumab)
1.2.10 Provenge (sipuleucel-T)
1.3 Urological Cancer Therapeutics Drugs Segment by Application
1.3.1 Global Urological Cancer Therapeutics Drugs Sales Comparison by Application (2020-2026)
1.3.2 Hospital
1.3.3 Medical Research Laboratory
1.3.4 Others
1.4 Urological Cancer Therapeutics Drugs Market Estimates and Forecasts (2015-2026)
1.4.1 Global Urological Cancer Therapeutics Drugs Sales Growth Rate (2015-2026)
1.4.2 Global Urological Cancer Therapeutics Drugs Revenue and Growth Rate (2015-2026)
1.4.3 Global Urological Cancer Therapeutics Drugs Price Trends (2015-2026)
2 Urological Cancer Therapeutics Drugs Estimate and Forecast by Region
2.1 Global Urological Cancer Therapeutics Drugs Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Urological Cancer Therapeutics Drugs Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Region (2015-2020)
2.2.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2015-2020)
2.3 Global Urological Cancer Therapeutics Drugs Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Urological Cancer Therapeutics Drugs Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Urological Cancer Therapeutics Drugs Estimates and Projections (2015-2026)
2.4.2 Europe Urological Cancer Therapeutics Drugs Estimates and Projections (2015-2026)
2.4.3 China Urological Cancer Therapeutics Drugs Estimates and Projections (2015-2026)
2.4.4 Japan Urological Cancer Therapeutics Drugs Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Urological Cancer Therapeutics Drugs Estimates and Projections (2015-2026)
2.4.6 India Urological Cancer Therapeutics Drugs Estimates and Projections (2015-2026)
3 Global Urological Cancer Therapeutics Drugs Competition Landscape by Players
3.1 Global Top Urological Cancer Therapeutics Drugs Players by Sales (2015-2020)
3.2 Global Top Urological Cancer Therapeutics Drugs Players by Revenue (2015-2020)
3.3 Global Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2019)
3.4 Global Urological Cancer Therapeutics Drugs Average Price by Company (2015-2020)
3.5 Manufacturers Urological Cancer Therapeutics Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Urological Cancer Therapeutics Drugs Players (Opinion Leaders)
4 Global Urological Cancer Therapeutics Drugs Market Size by Type
4.1 Global Urological Cancer Therapeutics Drugs Historic Market Review by Type (2015-2020)
4.1.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
4.1.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2015-2020)
4.1.3 Global Urological Cancer Therapeutics Drugs Price by Type (2015-2020)
4.2 Global Urological Cancer Therapeutics Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Global Urological Cancer Therapeutics Drugs Price Forecast by Type (2021-2026)
5 Global Urological Cancer Therapeutics Drugs Market Size by Application
5.1 Global Urological Cancer Therapeutics Drugs Historic Market Review by Application (2015-2020)
5.1.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
5.1.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2015-2020)
5.1.3 Global Urological Cancer Therapeutics Drugs Price by Application (2015-2020)
5.2 Global Urological Cancer Therapeutics Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Urological Cancer Therapeutics Drugs Price Forecast by Application (2021-2026)
6 United States Urological Cancer Therapeutics Drugs Market Facts & Figures
6.1 United States Urological Cancer Therapeutics Drugs Sales Market Share by Company (2015-2020)
6.2 United States Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
6.3 United States Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
7 Europe Urological Cancer Therapeutics Drugs Market Facts & Figures
7.1 Europe Urological Cancer Therapeutics Drugs Sales Market Share by Company (2015-2020)
7.2 Europe Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
7.3 Europe Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
8 China Urological Cancer Therapeutics Drugs Market Facts & Figures
8.1 China Urological Cancer Therapeutics Drugs Sales Market Share by Company (2015-2020)
8.2 China Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
8.3 China Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
9 Japan Urological Cancer Therapeutics Drugs Market Facts & Figures
9.1 Japan Urological Cancer Therapeutics Drugs Sales Market Share by Company (3015-3030)
9.2 Japan Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
9.3 Japan Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
10 Southeast Asia Urological Cancer Therapeutics Drugs Market Facts & Figures
10.1 Southeast Asia Urological Cancer Therapeutics Drugs Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
11 India Urological Cancer Therapeutics Drugs Market Facts & Figures
11.1 India Urological Cancer Therapeutics Drugs Sales Market Share by Company (2015-2020)
11.2 India Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
11.3 India Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Urological Cancer Therapeutics Drugs Business
12.1 Novartis
12.1.1 Novartis Corporation Information
12.1.2 Novartis Business Overview
12.1.3 Novartis Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Novartis Urological Cancer Therapeutics Drugs Products Offered
12.1.5 Novartis Recent Development
12.2 Pfizer
12.2.1 Pfizer Corporation Information
12.2.2 Pfizer Business Overview
12.2.3 Pfizer Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Pfizer Urological Cancer Therapeutics Drugs Products Offered
12.2.5 Pfizer Recent Development
12.3 Johnson & Johnson
12.3.1 Johnson & Johnson Corporation Information
12.3.2 Johnson & Johnson Business Overview
12.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Products Offered
12.3.5 Johnson & Johnson Recent Development
12.4 AstraZeneca
12.4.1 AstraZeneca Corporation Information
12.4.2 AstraZeneca Business Overview
12.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Products Offered
12.4.5 AstraZeneca Recent Development
12.5 Astellas
12.5.1 Astellas Corporation Information
12.5.2 Astellas Business Overview
12.5.3 Astellas Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Astellas Urological Cancer Therapeutics Drugs Products Offered
12.5.5 Astellas Recent Development
12.6 Bristol-Myers Squibb
12.6.1 Bristol-Myers Squibb Corporation Information
12.6.2 Bristol-Myers Squibb Business Overview
12.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Products Offered
12.6.5 Bristol-Myers Squibb Recent Development
12.7 Abbott Laboratories
12.7.1 Abbott Laboratories Corporation Information
12.7.2 Abbott Laboratories Business Overview
12.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Products Offered
12.7.5 Abbott Laboratories Recent Development
12.8 Celgene Corporation
12.8.1 Celgene Corporation Corporation Information
12.8.2 Celgene Corporation Business Overview
12.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Products Offered
12.8.5 Celgene Corporation Recent Development
12.9 Dendreon Corporation
12.9.1 Dendreon Corporation Corporation Information
12.9.2 Dendreon Corporation Business Overview
12.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Products Offered
12.9.5 Dendreon Corporation Recent Development
12.10 Ferring Pharmaceuticals
12.10.1 Ferring Pharmaceuticals Corporation Information
12.10.2 Ferring Pharmaceuticals Business Overview
12.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Products Offered
12.10.5 Ferring Pharmaceuticals Recent Development
12.11 GlaxoSmithKline plc
12.11.1 GlaxoSmithKline plc Corporation Information
12.11.2 GlaxoSmithKline plc Business Overview
12.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.11.4 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Products Offered
12.11.5 GlaxoSmithKline plc Recent Development
12.12 Indevus Pharmaceuticals Inc
12.12.1 Indevus Pharmaceuticals Inc Corporation Information
12.12.2 Indevus Pharmaceuticals Inc Business Overview
12.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Products Offered
12.12.5 Indevus Pharmaceuticals Inc Recent Development
12.13 Ipsen
12.13.1 Ipsen Corporation Information
12.13.2 Ipsen Business Overview
12.13.3 Ipsen Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Ipsen Urological Cancer Therapeutics Drugs Products Offered
12.13.5 Ipsen Recent Development
12.14 Roche Healthcare
12.14.1 Roche Healthcare Corporation Information
12.14.2 Roche Healthcare Business Overview
12.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Roche Healthcare Urological Cancer Therapeutics Drugs Products Offered
12.14.5 Roche Healthcare Recent Development
12.15 Sanofi S.A.
12.15.1 Sanofi S.A. Corporation Information
12.15.2 Sanofi S.A. Business Overview
12.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Sanofi S.A. Urological Cancer Therapeutics Drugs Products Offered
12.15.5 Sanofi S.A. Recent Development
13 Urological Cancer Therapeutics Drugs Manufacturing Cost Analysis
13.1 Urological Cancer Therapeutics Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs
13.4 Urological Cancer Therapeutics Drugs Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Urological Cancer Therapeutics Drugs Distributors List
14.3 Urological Cancer Therapeutics Drugs Customers
15 Market Dynamics
15.1 Urological Cancer Therapeutics Drugs Market Trends
15.2 Urological Cancer Therapeutics Drugs Opportunities and Drivers
15.3 Urological Cancer Therapeutics Drugs Market Challenges
15.4 Urological Cancer Therapeutics Drugs Market Restraints
15.5 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Urological Cancer Therapeutics Drugs Sales (K MT) Growth Rate by Type (2020-2026) (US$ Million)
Table 2. Global Urological Cancer Therapeutics Drugs Sales (K MT) Comparison by Application (2020-2026) (US$ Million)
Table 3. Global Market Urological Cancer Therapeutics Drugs Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Region (2015-2020)
Table 5. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region (2015-2020)
Table 6. Global Urological Cancer Therapeutics Drugs Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Urological Cancer Therapeutics Drugs Revenue Share by Region (2015-2020)
Table 8. Global Urological Cancer Therapeutics Drugs Sales (K MT) Forecast by Region (2021-2026)
Table 9. Global Urological Cancer Therapeutics Drugs Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Urological Cancer Therapeutics Drugs Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Urological Cancer Therapeutics Drugs Revenue Share Forecast by Region (2021-2026)
Table 12. Global Urological Cancer Therapeutics Drugs (K MT) of Key Companies (2015-2020)
Table 13. Global Urological Cancer Therapeutics Drugs Sales Share by Company (2015-2020)
Table 14. Global Urological Cancer Therapeutics Drugs Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Urological Cancer Therapeutics Drugs Revenue Share by Company (2015-2020)
Table 16. Global Urological Cancer Therapeutics Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2019)
Table 17. Global Urological Cancer Therapeutics Drugs Average Price (USD/MT) of Key Company (2015-2020)
Table 18. Manufacturers Urological Cancer Therapeutics Drugs Manufacturing Sites and Area Served
Table 19. Manufacturers Urological Cancer Therapeutics Drugs Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Urological Cancer Therapeutics Drugs Players
Table 22. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2015-2020)
Table 23. Global Urological Cancer Therapeutics Drugs Sales Share by Type (2015-2020)
Table 24. Global Urological Cancer Therapeutics Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Urological Cancer Therapeutics Drugs Price (K MT) by Type (2015-2020)
Table 26. Global Urological Cancer Therapeutics Drugs Sales Share by Type (2021-2026)
Table 27. Global Urological Cancer Therapeutics Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Urological Cancer Therapeutics Drugs Revenue Share by Type (2021-2026)
Table 29. Global Urological Cancer Therapeutics Drugs Price (K MT) by Type (2021-2026)
Table 30. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Application (2015-2020)
Table 31. Global Urological Cancer Therapeutics Drugs Sales Share by Application (2015-2020)
Table 32. Global Urological Cancer Therapeutics Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Urological Cancer Therapeutics Drugs Price (K MT) by Application (2015-2020)
Table 34. Global Urological Cancer Therapeutics Drugs Sales (K MT) by Application (2021-2026)
Table 35. Global Urological Cancer Therapeutics Drugs Sales Share by Application (2021-2026)
Table 36. Global Urological Cancer Therapeutics Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Urological Cancer Therapeutics Drugs Revenue Share by Application (2021-2026)
Table 38. Global Urological Cancer Therapeutics Drugs Price (K MT) by Application (2021-2026)
Table 39. United States Urological Cancer Therapeutics Drugs Sales (K MT) by Company (2015-2020)
Table 40. United States Urological Cancer Therapeutics Drugs Sales Market Share by Company (2015-2020)
Table 41. United States Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2015-2020)
Table 42. United States Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
Table 43. United States Urological Cancer Therapeutics Drugs Sales (K MT) by Application (2015-2020)
Table 44. United States Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
Table 45. Europe Urological Cancer Therapeutics Drugs Sales (K MT) by Company (2015-2020)
Table 46. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Company (2015-2020)
Table 47. Europe Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2015-2020)
Table 48. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
Table 49. Europe Urological Cancer Therapeutics Drugs Sales (K MT) by Application (2015-2020)
Table 50. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
Table 51. China Urological Cancer Therapeutics Drugs Sales (K MT) by Company (2015-2020)
Table 52. China Urological Cancer Therapeutics Drugs Sales Market Share by Company (2015-2020)
Table 53. China Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2015-2020)
Table 54. China Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
Table 55. China Urological Cancer Therapeutics Drugs Sales (K MT) by Application (2015-2020)
Table 56. China Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
Table 57. Japan Urological Cancer Therapeutics Drugs Sales (K MT) by Company (2015-2020)
Table 58. Japan Urological Cancer Therapeutics Drugs Sales Market Share by Company (2015-2020)
Table 59. Japan Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2015-2020)
Table 60. Japan Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
Table 61. Japan Urological Cancer Therapeutics Drugs Sales (K MT) by Application (2015-2020)
Table 62. Japan Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Urological Cancer Therapeutics Drugs Sales (K MT) by Company (2015-2020)
Table 64. Southeast Asia Urological Cancer Therapeutics Drugs Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2015-2020)
Table 66. Southeast Asia Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2015-2020)
Table 68. Southeast Asia Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
Table 69. India Urological Cancer Therapeutics Drugs Sales (K MT) by Company (2015-2020)
Table 70. India Urological Cancer Therapeutics Drugs Sales Market Share by Company (2015-2020)
Table 71. India Urological Cancer Therapeutics Drugs Sales (K MT) by Type (2015-2020)
Table 72. India Urological Cancer Therapeutics Drugs Sales Market Share by Type (2015-2020)
Table 73. India Urological Cancer Therapeutics Drugs Sales (K MT) by Application (2015-2020)
Table 74. India Urological Cancer Therapeutics Drugs Sales Market Share by Application (2015-2020)
Table 75. Novartis Corporation Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 78. Novartis Urological Cancer Therapeutics Drugs Product
Table 79. Novartis Recent Development
Table 80. Pfizer Corporation Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 83. Pfizer Urological Cancer Therapeutics Drugs Product
Table 84. Pfizer Recent Development
Table 85. Johnson & Johnson Corporation Information
Table 86. Johnson & Johnson Description and Business Overview
Table 87. Johnson & Johnson Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 88. Johnson & Johnson Urological Cancer Therapeutics Drugs Product
Table 89. Johnson & Johnson Recent Development
Table 90. AstraZeneca Corporation Information
Table 91. AstraZeneca Description and Business Overview
Table 92. AstraZeneca Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 93. AstraZeneca Urological Cancer Therapeutics Drugs Product
Table 94. AstraZeneca Recent Development
Table 95. Astellas Corporation Information
Table 96. Astellas Description and Business Overview
Table 97. Astellas Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 98. Astellas Urological Cancer Therapeutics Drugs Product
Table 99. Astellas Recent Development
Table 100. Bristol-Myers Squibb Corporation Information
Table 101. Bristol-Myers Squibb Description and Business Overview
Table 102. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 103. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product
Table 104. Bristol-Myers Squibb Recent Development
Table 105. Abbott Laboratories Corporation Information
Table 106. Abbott Laboratories Description and Business Overview
Table 107. Abbott Laboratories Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 108. Abbott Laboratories Urological Cancer Therapeutics Drugs Product
Table 109. Abbott Laboratories Recent Development
Table 110. Celgene Corporation Corporation Information
Table 111. Celgene Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 112. Celgene Corporation Description and Business Overview
Table 113. Celgene Corporation Urological Cancer Therapeutics Drugs Product
Table 114. Celgene Corporation Recent Development
Table 115. Dendreon Corporation Corporation Information
Table 116. Dendreon Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 117. Dendreon Corporation Description and Business Overview
Table 118. Dendreon Corporation Urological Cancer Therapeutics Drugs Product
Table 119. Dendreon Corporation Recent Development
Table 120. Ferring Pharmaceuticals Corporation Information
Table 121. Ferring Pharmaceuticals Description and Business Overview
Table 122. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 123. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product
Table 124. Ferring Pharmaceuticals Recent Development
Table 125. GlaxoSmithKline plc Corporation Information
Table 126. GlaxoSmithKline plc Description and Business Overview
Table 127. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 128. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product
Table 129. GlaxoSmithKline plc Recent Development
Table 130. Indevus Pharmaceuticals Inc Corporation Information
Table 131. Indevus Pharmaceuticals Inc Description and Business Overview
Table 132. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 133. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product
Table 134. Indevus Pharmaceuticals Inc Recent Development
Table 135. Ipsen Corporation Information
Table 136. Ipsen Description and Business Overview
Table 137. Ipsen Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 138. Ipsen Urological Cancer Therapeutics Drugs Product
Table 139. Ipsen Recent Development
Table 140. Roche Healthcare Corporation Information
Table 141. Roche Healthcare Description and Business Overview
Table 142. Roche Healthcare Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 143. Roche Healthcare Urological Cancer Therapeutics Drugs Product
Table 144. Roche Healthcare Recent Development
Table 145. Sanofi S.A. Corporation Information
Table 146. Sanofi S.A. Description and Business Overview
Table 147. Sanofi S.A. Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 148. Sanofi S.A. Urological Cancer Therapeutics Drugs Product
Table 149. Sanofi S.A. Recent Development
Table 150. Production Base and Market Concentration Rate of Raw Material
Table 151. Key Suppliers of Raw Materials
Table 152. Urological Cancer Therapeutics Drugs Distributors List
Table 153. Urological Cancer Therapeutics Drugs Customers List
Table 154. Urological Cancer Therapeutics Drugs Market Key Trends
Table 155. Urological Cancer Therapeutics Drugs Key Opportunities and Drivers
Table 156. Urological Cancer Therapeutics Drugs Market Challenges
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Urological Cancer Therapeutics Drugs Product Picture
Figure 2. Global Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Urological Cancer Therapeutics Drugs Market Share by Application in 2020 & 2026
Figure 6. Hospital Examples
Figure 7. Medical Research Laboratory Examples
Figure 8. Others Examples
Figure 9. Global Urological Cancer Therapeutics Drugs Sales (K MT) Growth Rate (2015-2026)
Figure 10. Global Urological Cancer Therapeutics Drugs Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Urological Cancer Therapeutics Drugs Price Trends Growth Rate (2015-2026) (USD/MT)
Figure 12. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Urological Cancer Therapeutics Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Urological Cancer Therapeutics Drugs Sales (K MT) Growth Rate (2015-2026)
Figure 16. Europe Urological Cancer Therapeutics Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Urological Cancer Therapeutics Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Urological Cancer Therapeutics Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Urological Cancer Therapeutics Drugs Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Urological Cancer Therapeutics Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Urological Cancer Therapeutics Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Urological Cancer Therapeutics Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Urological Cancer Therapeutics Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Urological Cancer Therapeutics Drugs Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Urological Cancer Therapeutics Drugs Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Urological Cancer Therapeutics Drugs Players Market Share by Revenue in Urological Cancer Therapeutics Drugs 2015 & 2019
Figure 27. Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Urological Cancer Therapeutics Drugs Revenue Share by Type (2015-2020)
Figure 29. Global Urological Cancer Therapeutics Drugs Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Urological Cancer Therapeutics Drugs Revenue Share by Application (2015-2020)
Figure 31. Global Urological Cancer Therapeutics Drugs Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2019
Figure 33. United States Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2019
Figure 34. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Company in 2019
Figure 35. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2019
Figure 36. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Application in 2019
Figure 37. China Urological Cancer Therapeutics Drugs Sales Market Share by Company in 2019
Figure 38. China Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2019
Figure 39. China Urological Cancer Therapeutics Drugs Sales Market Share by Application in 2019
Figure 40. Japan Urological Cancer Therapeutics Drugs Sales Market Share by Company in 2019
Figure 41. Japan Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2019
Figure 42. Japan Urological Cancer Therapeutics Drugs Sales Market Share by Application in 2019
Figure 43. Southeast Asia Urological Cancer Therapeutics Drugs Sales Market Share by Company in 2019
Figure 44. Southeast Asia Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2019
Figure 45. Southeast Asia Urological Cancer Therapeutics Drugs Sales Market Share by Application in 2019
Figure 46. India Urological Cancer Therapeutics Drugs Sales Market Share by Company in 2019
Figure 47. India Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2019
Figure 48. India Urological Cancer Therapeutics Drugs Sales Market Share by Application in 2019
Figure 49. Key Raw Materials Price Trend
Figure 50. Manufacturing Cost Structure of Urological Cancer Therapeutics Drugs
Figure 51. Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs
Figure 52. Urological Cancer Therapeutics Drugs Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Porter's Five Forces Analysis
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
乳がん治療薬の世界市場レポート2020 Medicines include tamoxifen (Nolvadex) for women before and after menopause and aromatase inhibitors including anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara) for postmenopausal women. Side effects can include hot flashes and vaginal dryness Market Analysis and Insights: Global…- トレプロスチニル薬の世界市場レポート2020 Treprostinil is a vasodilator that is used for the treatment of pulmonary arterial hypertension. North America is the largest consumption place, with a consumption market share nearly 92% in 2018. Following North America, Europe are also very important market with the consumption market share of 6.8…
- 多発性硬化症（MS）治療薬の世界市場レポート2020 Market Analysis and Insights: Global Multiple Sclerosis (MS) Drugs Market The global Multiple Sclerosis (MS) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Multiple Sclerosis (MS) Drugs Scope and Market Size The …
- 海洋由来薬品の世界市場レポート2020 Most marine-derived compounds possess a few defining characteristics. First, often very low doses are given to patients, and they are administered almost exclusively via intravenous infusion (i.v.). The compounds are typically large molecules, especially the depsipeptides, and they are often hydroph…
- 血液脳関門輸送薬の世界市場レポート2020 Market Analysis and Insights: Global Blood-Brain Barrier Transport Drugs Market The global Blood-Brain Barrier Transport Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Blood-Brain Barrier Transport Drugs Scope an…